MedTrace Logo

Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome

NCT04351906 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-03-04

No results posted yet for this study

Summary

The study aims to investigate the efficacy of extracorporeal CO2 removal for correction of hypercapnia in coronavirus disease 19 (COVID-19)-associated acute respiratory distress syndrome

Conditions

  • ARDS
  • Hypercapnic Respiratory Failure
  • AKI

Interventions

DEVICE

ECCO2R

ECCO2R integrated into the multiFiltrate device

Sponsors & Collaborators

  • University of Giessen

    lead OTHER

Principal Investigators

  • Werner Seeger, MD · University Hospital Giessen and Marburg, Giessen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-03
Primary Completion
2024-06-30
Completion
2024-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04351906 on ClinicalTrials.gov